Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study
Authors
Keywords
Breast stem cells, mTOR, Aromatase, Everolimus, Letrozole
Journal
TUMOR BIOLOGY
Volume 35, Issue 2, Pages 1275-1286
Publisher
Springer Nature
Online
2013-09-07
DOI
10.1007/s13277-013-1170-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
- (2013) Xiaobei Zhang et al. CURRENT CANCER DRUG TARGETS
- Effects of the combination of RAD001 and docetaxel on breast cancer stem cells
- (2012) Xiaobei Zhang et al. EUROPEAN JOURNAL OF CANCER
- Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo
- (2012) Yuanxi Zhu et al. TUMOR BIOLOGY
- The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells
- (2011) Yi Ma et al. BREAST CANCER RESEARCH AND TREATMENT
- mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy
- (2011) Ruth O'Regan et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo
- (2011) Cheng-Xiong Xu et al. PLoS One
- Characterization of AKT independent effects of the synthetic AKT inhibitors SH-5 and SH-6 using an integrated approach combining transcriptomic profiling and signaling pathway perturbations
- (2010) Till Krech et al. BMC CANCER
- Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors
- (2010) S. Akli et al. CLINICAL CANCER RESEARCH
- Expression of the K303R Estrogen Receptor- Breast Cancer Mutation Induces Resistance to an Aromatase Inhibitor via Addiction to the PI3K/Akt Kinase Pathway
- (2009) I. Barone et al. CANCER RESEARCH
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibitor hijacking of Akt activation
- (2009) Tatsuya Okuzumi et al. Nature Chemical Biology
- Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
- (2009) Sandra Ghayad et al. Recent Patents on Anti-Cancer Drug Discovery
- Determinants ofRASistance to Anti–Epidermal Growth Factor Receptor Agents
- (2008) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search